Coya Therapeutics, Inc. (COYA) Insider Trading Activity
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
COYA Insider Trading Activity
COYA Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $106,393 | 4 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Swaminathan Arun | Chief Executive Officer | 2 | $73,486 | 0 | $0 | $73,486 |
| Grossman Fred | Chief Medical Officer | 1 | $19,973 | 0 | $0 | $19,973 |
| SNYDER DAVID S | Chief Financial Officer | 1 | $12,934 | 0 | $0 | $12,934 |
About Coya Therapeutics, Inc.
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.
Insider Activity of Coya Therapeutics, Inc.
Over the last 12 months, insiders at Coya Therapeutics, Inc. have bought $106,393 and sold $0 worth of Coya Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Coya Therapeutics, Inc. have bought $36,671 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Swaminathan Arun (Chief Executive Officer) — $73,486. Grossman Fred (Chief Medical Officer) — $19,973. SNYDER DAVID S (Chief Financial Officer) — $12,934.
The last purchase of 1,800 shares for transaction amount of $12,934 was made by SNYDER DAVID S (Chief Financial Officer) on 2024‑11‑14.
List of Insider Buy and Sell Transactions, Coya Therapeutics, Inc.
| 2024-11-14 | SNYDER DAVID S | Chief Financial Officer | 1,800 0.0126% | $7.19 | $12,934 | -9.40% | ||
| 2024-11-13 | Swaminathan Arun | Chief Executive Officer | 5,000 0.0335% | $7.36 | $36,797 | -14.71% | ||
| 2024-11-11 | Swaminathan Arun | Chief Executive Officer | 5,000 0.0336% | $7.34 | $36,689 | -15.55% | ||
| 2024-11-11 | Grossman Fred | Chief Medical Officer | 2,710 0.0183% | $7.37 | $19,973 | -15.55% | ||
| 2023-08-22 | Lee Ann | director | 1,000 0.0104% | $3.62 | $3,620 | +94.16% | ||
| 2023-01-03 | Villalobos Anabella | director | 10,000 – | $0 | $0 | -2.15% | ||
| 2023-01-03 | Lee Ann | director | 10,000 – | $0 | $0 | -2.15% | ||
| 2023-01-03 | Hepner Adrian | Chief Medical Officer | 10,000 – | $0 | $0 | -2.15% | ||
| 2023-01-03 | GOLDSTEIN DOV A MD | director | 10,000 – | $0 | $0 | -2.15% | ||
| 2023-01-03 | Berman Howard | Chief Executive Officer | 10,000 – | $0 | $0 | -2.15% | ||
| 2023-01-03 | SNYDER DAVID S | Chief Financial Officer | 7,000 – | $0 | $0 | -2.15% | ||
| 2023-01-03 | Garren Hideki | director | 2,000 – | $0 | $0 | -2.15% |
Insider Historical Profitability
| Swaminathan Arun | Chief Executive Officer | 10000 0.0598% | $57,600.00 | 2 | 0 | |
| SNYDER DAVID S | Chief Financial Officer | 8800 0.0526% | $50,688.00 | 2 | 0 | |
| Grossman Fred | Chief Medical Officer | 2710 0.0162% | $15,609.60 | 1 | 0 | |
| Lee Ann | director | 17479 0.1045% | $100,679.04 | 2 | 0 | +94.16% |
| GOLDSTEIN DOV A MD | director | 10000 0.0598% | $57,600.00 | 1 | 0 | |
| Hepner Adrian | Chief Medical Officer | 10000 0.0598% | $57,600.00 | 1 | 0 | |
| Villalobos Anabella | director | 10000 0.0598% | $57,600.00 | 1 | 0 | |
| Berman Howard | Chief Executive Officer | 10000 0.0598% | $57,600.00 | 1 | 0 | |
| Garren Hideki | director | 2000 0.012% | $11,520.00 | 1 | 0 |
Historical Insider Profitability vs. Competitors
$54,751,750 | 62 | -1.03% | $107.33M | |
$48,218,096 | 42 | 0.89% | $105.43M | |
$16,245,616 | 40 | 123.58% | $94.82M | |
$140,938,207 | 36 | 14.75% | $91.84M | |
$35,092,436 | 31 | 38.62% | $98.94M | |
$36,079,815 | 31 | 43.23% | $94.84M | |
$63,049,419 | 31 | 2.87% | $109.89M | |
$40,617,659 | 23 | 2.15% | $97.16M | |
$1,239,833 | 16 | 53.23% | $94.25M | |
$178,593,887 | 15 | -14.86% | $109.39M | |
$272,982 | 6 | -28.53% | $91.92M | |
$556,839 | 5 | 13.42% | $106.51M | |
$30,149,552 | 3 | -66.74% | $96.27M | |
$16,003,671 | 3 | 55.38% | $95.63M | |
$9,999,990 | 2 | 25.53% | $93.95M | |
$63,731 | 1 | -19.50% | $97.55M | |
$1,250 | 1 | 278.21% | $93.58M | |
$20,020,000 | 1 | -75.24% | $100.27M | |
Coya Therapeutics, Inc. (COYA) | $3,620 | 1 | 94.16% | $96.34M |
COYA Institutional Investors: Active Positions
| Increased Positions | 20 | +125% | 808,345 | +20.73% |
| Decreased Positions | 6 | -37.5% | 64,378 | -1.65% |
| New Positions | 9 | New | 364,926 | New |
| Sold Out Positions | 3 | Sold Out | 41,306 | Sold Out |
| Total Postitions | 30 | +87.5% | 5M | +19.08% |
COYA Ownership Change vs Market
Institutional Investor Ownership
| Dme Capital Management, Lp | $10,488.00 | 9.69% | 1.65M | +372,414 | +29.23% | 2024-12-31 |
| Aigh Capital Management Llc | $7,651.00 | 7.07% | 1.2M | +551,725 | +84.96% | 2024-12-31 |
| Vanguard Group Inc | $5,354.00 | 4.94% | 840,471 | -4,953 | -0.59% | 2024-12-31 |
| Cm Management, Llc | $1,019.00 | 0.94% | 160,000 | +15,941 | +11.07% | 2024-12-31 |
| Geode Capital Management, Llc | $959.00 | 0.89% | 150,576 | +8,267 | +5.81% | 2024-12-31 |
| Blackrock, Inc. | $534.00 | 0.49% | 83,795 | +7,602 | +9.98% | 2025-03-31 |
| Newbridge Financial Services Group, Inc. | $446.00 | 0.41% | 70,000 | +70,000 | New | 2024-12-31 |
| State Street Corp | $306.00 | 0.28% | 48,100 | +5,100 | +11.86% | 2024-12-31 |
| Ubs Group Ag | $274.00 | 0.25% | 43,026 | +43,026 | New | 2024-12-31 |
| Prelude Capital Management, Llc | $228.00 | 0.21% | 35,770 | 0 | 0% | 2024-12-31 |